Personalizing Bispecific Antibody Therapy for Your Patients With Multiple Myeloma: Clinical Fundamentals, Current Evidence, and Expert Strategies for Community HCPs

In this textbased module a clinical hematologist reviews the rapidly evolving role of bispecific antibodies BsAbs in multiple myeloma with a focus on BCMA and GPRC5Ddirected therapies their mechanisms of action pivotal and emerging clinical trial data and characteristic safety considerations such as cytokine release syndrome neurotoxicity infection risk and targetspecific adverse events The faculty also examines the use of these agents in heavily pretreated disease and their movement into earlier treatment settings and combination regimens while also addressing sequencing after prior BCMAdirected therapy potential mechanisms of treatment failure and the relative clinical and logistical considerations of BsAbs vs CAR Tcell therapy By integrating efficacy durability safety sequencing and realworld feasibility this module will help you evaluate where BsAbs may fit within individualized treatment strategies for patients with relapsedrefractory multiple myeloma

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

On-demand / recorded video
includes Online course / module
Credit · Up to 0.5 credits
MOC · Up to 0.5 points
Commercial Support

Released

Aug 18, 2026
Last day to claim credit

Feb 18, 2027 4 months left

Personalizing Bispecific Antibody Therapy for Your Patients With Multiple Myeloma: Clinical Fundamentals, Current Evidence, and Expert Strategies for Community HCPs

More from Clinical Care Options, LLC (dba Decera Clinical Education)

Related courses